Sequential Development of Histiocytic Sarcoma and Diffuse Large B-cell Lymphoma in a Patient With a Remote History of Follicular Lymphoma With Genotypic Evidence of a Clonal Relationship

Endi Wang(University of Southern California), Michael Datto(Duke University), Catherine Rehder(Duke University), Charles Blake Hutchinson(Duke University), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Evan Kulbacki, John A. Papalas, Joseph O. Moore(Cancer Institute (WIA)), Siby Sebastian(Duke University), Damian Silbermins(Duke Medical Center)
The American Journal of Surgical Pathology
February 12, 2011
10.1097/pas.0b013e3182098799
Cited by 58

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver.
|Journal of Biological Chemistry|1993|375
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Leukemia|2012|362